BioSpace News Archive

Brainomix, an Oxford-based company specializing in the creation of AI-powered imaging biomarkers to enable precision medicine for better treatment decisions, today announced two new additions to its Board of Directors, with the appointment of Professor Jacqueline (“Jackie”) Hunter as Chairperson and Professor Heinz-Otto

Bladder cancer diagnostics provider, Pacific Edge Diagnostics, has been notified by Novitas1 that the LCD: Biomarkers for Oncology (L35396) provides coverage for Cxbladder (0012M and 0013M) for tests performed on or after July 1, 2020 that are medically necessary. This LCD coverage enables national reimbursement for Cxbladder tests performed among the approximately 62 million people who have Medicare coverage with the Centers for Medicare

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Trodelvy (sacituzumab govitecan-hziy) orphan status for the treatment of adult and pediatric patients with glioblastoma. “Glioblastoma is an aggressive cancer with a la

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced today it has received the 2020 Rare Impact Award®for Industry Innovation from the National Organization for Rare Disorders (NORD).

Rhizen Pharmaceuticals S. A. (Rhizen), a Switzerland-based privately held clinical-stage biopharmaceutical company, and Curon Biopharmaceutical Limited (Curon), a clinical-stage innovative biopharmaceutical company with facility in Shanghai announced today that they have entered into an exclusive licensing agreement for the development and commercialization of Tenalisib, a dual PI3K delta &a

TFS recently entered into a strategic partnership with the Duke Clinical Research Institute (DCRI) to provide data management solutions across the academic research organization’s study portfolio. The partnership supports TFS’s growth strategy and aligns its clinical development services with an organization renowned for bringing

MedAlliance has announced enrolment of the first two patients in the PRISTINE registry with SELUTION SLR™ 018 DEB for the treatment of patients with Below The Knee disease (Chronic Limb Threatening Ischemia). This is the first DEB accepted by the FDA for its “Breakthrough Program”. SELUTION SLR (Sustained Limus Release) is a nov

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today introduced two new SARS-CoV-2 antibody tests: the Thermo Scientific OmniPATH COVID-19 Total Antibody ELISA test, and the Thermo Scientific EliA SARS-CoV-2-Sp1 IgG test. These new tests for detecting COVID-19 antibodies expand the company’s leading

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases

Newly disclosed data build on topline results and continue to support GB004’s differentiated approach of targeting epithelial barrier restoration in patients with ulcerative colitis - - GB004 demonstrated superior barrier protection compared to tofacitinib in pre-clinical human monolayer assay - - S HIF T-UC Phase 2 study active and screening patients for enrollment - SAN DIEGO--( BUSINESS WIRE )-- Gossamer Bio, Inc. (Nasdaq: GOSS),